Matrimony.com Q1 FY27 results: Revenue Rs 130 Cr, PAT Rs 19 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Five pros including Loratadine API leadership and Dr Morepen OTC brand, and four cons including inconsistent profitability and regulatory risk, of Morepen Laboratories share.

Five pros including novel antibiotic drug pipeline and turnaround potential, and four cons including high debt legacy and clinical risk, of Wockhardt share.

SEPC Q1 FY27 results: Revenue Rs 273 Cr, Net Loss Rs 11 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Syncom Formulations Q1 FY27 results: Revenue Rs 125 Cr, PAT Rs 24 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

EPack Durables Q1 FY27 results: Revenue Rs 886 Cr, PAT Rs 14 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Macfos Q1 FY27 results: Revenue Rs 81 Cr, PAT Rs 5 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Diffusion Engineers Q1 FY27 results: Revenue Rs 110 Cr, PAT Rs 12 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Precision Camshafts Q1 FY27 results: Revenue Rs 187 Cr, PAT Rs 8 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

Quadrant Future Tek Q1 FY27 results: Revenue Rs 40 Cr, Net Loss Rs 9 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.